#1
#1 out of 1
health12h ago
Exclusive: In major test for longevity field, FDA greenlights study on a 'near total reset' of cells
- The FDA has greenlit a gene therapy study by Life Biosciences, marking a notable regulatory milestone in longevity research.
- The trial aims at a near-total reset of cells, a concept central to theories about aging and potential reversal.
- R&D cell and gene therapy developments remain a focal point as the field moves toward experimental therapies and regulatory scrutiny.
- The report notes additional near-term developments, including mid-stage obesity results and phase 3 inquiries into gene editing.
- Insilico and other firms are highlighted for recent deal activity linked to data delivery and clinical timing.
- The exclusive has implications for investors and policymakers tracking the pace of regenerative medicine.
- The article emphasizes the high-stakes nature of aging research and potential healthcare impacts.
- Readers are invited to sign up for full access to the exclusive content and related newsletters.
- The piece compiles current industry context around biotech advances in gene therapy and longevity.
Vote 0